Monteris Medical, Inc.
350 East Michigan Avenue
39 articles with Monteris Medical, Inc.
Monteris Medical Announces Health Care Service Corporation Policy Coverage for its NeuroBlate® System Laser Interstitial Thermotherapy for Brain Tumors and Epilepsy
Monteris Medical, the leader in MRI-guided laser interstitial thermotherapy, announced that health insurance provider Health Care Service Corporation, one of the largest independent licensees of Blue Cross and Blue Shield Association®, has updated its medical coverage policy allowing access to the minimally invasive laser ablation procedure for brain tumors and epilepsy when medically necessary.
Monteris Medical Announces Publication of First Prospective Multicenter Study of Minimally Invasive Laser Ablation for Drug Resistant Epilepsy
Monteris Medical announced today the publication of results from a multicenter clinical study with its NeuroBlate® System for the treatment of drug resistant epilepsy have been published in the peer-reviewed journal Epilepsy Research. The paper describes data from the LAANTERN prospective multicenter registry, sponsored by
Monteris Medical announced today that the application for two new Category Level I CPT® code(s) for laser interstitial thermal therapy (LITT) of intracranial lesion, with magnetic resonance (MR) imaging guidance has been accepted by the American Medical Association (AMA) CPT® (Current Procedure Terminology) Editorial Panel. This
Study Suggests Potential Role for Laser Ablation in Glioblastoma Treatment, Monteris Medical Announces
Researchers at the Washington University School of Medicine in St. Louis, Mo., led by neurosurgeon Dr. Albert H. Kim, found direct evidence in mice that the focal thermal effect of laser interstitial thermal therapy opens the blood-brain barrier and blood-tumor barrier.
Monteris Medical Announces Blue Cross Blue Shield of North Carolina Expands Policy Coverage for its NeuroBlate® System Laser Interstitial Thermotherapy for Brain Tumor
Monteris Medical, the leader in MRI-guided laser interstitial thermotherapy, is pleased to announce that health insurance provider Blue Cross Blue Shield of North Carolina has updated its medical coverage policy allowing access to the minimally invasive surgical option using laser ablation for brain tumor patients when medically necessary.
Monteris Medical announced that it has received FDA clearance of its NeuroBlate Fusion-S Software and released the product commercially. This latest innovation for the NeuroBlate System has now been used in over 200 cases
Monteris Medical , the leader in image-guided laser interstitial thermotherapy (LITT), announced today that it has reached a significant milestone: surgeons have used the company's minimally invasive NeuroBlate® System
The award recognizes Monteris Medical founders Mark G. Torchia and Richard Tyc for the development of the minimally invasive NeuroBlate® System
Monteris Medical Announces Anthem, Inc. Has Developed Clinical Utilization Management Guidelines for its NeuroBlate® System Laser Interstitial Thermotherapy for Refractory Epilepsy
Monteris Medical, the leader in image-guided laser interstitial thermotherapy (LITT), is pleased to announce that health insurance provider Anthem, Inc. has established Clinical Utilization Management (UM) Guidelines for LITT allowing access to a minimally invasive surgical option to its beneficiaries with refractory epilepsy when the established medical necessity criteria have been met.
Monteris Medical Announces Aetna Coverage of its NeuroBlate® System Laser Interstitial Thermotherapy for Refractory Epilepsy
With this expanded coverage from one of the country's largest health care insurance companies, the minimally-invasive NeuroBlate System can now be made available to more patients suffering from refractory epilepsy
Monteris Medical Announces the Publication of Positive Clinical Data for Its NeuroBlate® Laser System for Patients with Brain Metastasis
The LAASR clinical study enrolled patients with brain lesions that recurred following stereotactic radiosurgery for metastatic brain cancer.
Monteris® Medical Announces FDA Clearance of Laser Probe with Fiber Optic Controlled Cooling for Use with the NeuroBlate® System
New NeuroBlate® Optic™ Laser Probe Replaces Metal Thermocouple with Non-Metallic Fiber Optic Temperature Sensor to Preserve Controlled Cooling and Ablation while Improving Safety Profile
The global MRI-guided neurosurgical ablation market is projected to expand at a CAGR of 4.9% during the forecast period 2018–2028 and reach US$ 216.3 Mn by the end of 2028.
Monteris Med Raises $26.6 Million In Series C Financing To Further The Growth Of The Neuroblate® System
Monteris Med Announces New Data From Clinical Studies Evaluating Laser Interstitial Thermal Therapy For Brain Lesions
Monteris Med Receives IDE Approval From FDA To Evaluate NeuroBlate In Patients Newly Diagnosed With Glioblastoma Multiforme